Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aurinia Pharmaceuticals Inc. (AUPH:NASDAQ), powered by AI.
Aurinia Pharmaceuticals Inc. is currently trading at $16.22. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aurinia Pharmaceuticals Inc. on Alpha Lenz.
Aurinia Pharmaceuticals Inc.'s P/E ratio is 7.6.
“Aurinia Pharmaceuticals Inc. trades at a P/E of 7.6 (undervalued) with strong ROE of 59.9%. 3Y revenue CAGR of 28.3% highlights clear growth momentum.”
Ask for details →Aurinia Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of novel therapies for the treatment of autoimmune diseases. The company's primary function is to advance therapeutic options that improve the lives of individuals suffering from debilitating autoimmune conditions. A standout feature of Aurinia Pharmaceuticals is its specialization in nephrology, which includes its flagship product designed to treat lupus nephritis, a severe manifestation of systemic lupus erythematosus impacting kidney function. Aurinia's research and development efforts concentrate on innovative drug platforms, leveraging scientific advancements to address unmet medical needs in the immune system disorders arena. As a key player in the biotech industry, Aurinia Pharmaceuticals contributes to significant advancements in personalized medicine and targeted therapy. By pushing the boundaries of conventional treatment options, the company plays a crucial role in expanding the horizons of autoimmune disease management within global healthcare markets.
“Aurinia Pharmaceuticals Inc. trades at a P/E of 7.6 (undervalued) with strong ROE of 59.9%. 3Y revenue CAGR of 28.3% highlights clear growth momentum.”
Ask for details →Aurinia Pharmaceuticals Inc. (ticker: AUPH) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 130 employees. Market cap is $2.2B.
The current price is $16.22 with a P/E ratio of 7.59x and P/B of 3.75x.
ROE is 59.91% and operating margin is 37.65%. Annual revenue is $283M.